# CVS Health: Fresh Value Insights and Analysis Newsy: Value Investor Weekly Published: 2025-11-06T13:30:00.439Z Source: https://newsyai.com/edition/14296628-8af4-4573-b2c2-a0db97e6451c Archive: https://newsyai.com/newsy/5bbbadf7-1e6d-4c85-a79b-15b39036f33d.md --- # Value Radar: Fresh Picks & a Full Valuation Deep‑Dive on CVS Health (CVS) Date: November 6, 2025 (United States) This research is for educational purposes only, not investment advice. Every key assumption below is documented so you can audit it. ## 10 fresh value candidates (quick scan) - CVS Health (CVS) — reset year with big non‑cash goodwill charge, but operations and cash flow improving; Q3 revenue record $102.9B, YTD operating cash flow $7.2B; 2025 Adjusted EPS guidance raised to $6.55–$6.65; dividend steady at $0.665/qtr. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) - Capital One (COF) — Discover deal approved by Fed/OCC, poised to own a full card network plus large issuer economics; closing targeted in 2025. ([apnews.com](https://apnews.com/article/325282003a930d608ad8d3d5d2383b66?utm_source=openai)) - Cboe Global Markets (CBOE) — record Q3 revenue/EPS; portfolio refocused on derivatives while exiting/lowering exposure in listings; guidance raised. ([ir.cboe.com](https://ir.cboe.com/news/news-details/2025/Cboe-Global-Markets-Reports-Results-for-Third-Quarter-2025-and-Announces-Strategic-Realignment-of-Business-Portfolio/default.aspx?utm_source=openai)) - Aflac (AFL) — strong Q3 adj. EPS +15% y/y; ongoing buybacks/dividends with high capital generation. ([investors.aflac.com](https://investors.aflac.com/press-releases/press-release-details/2025/Aflac-Incorporated-Announces-Third-Quarter-Results-Reports-Third-Quarter-Net-Earnings-of-1-6-Billion-Declares-Fourth-Quarter-Dividend/default.aspx?utm_source=openai)) - Valero (VLO) — heavy cash returns (78% of Q3 adjusted operating cash); low net leverage; throughput guide intact. ([fool.com](https://www.fool.com/earnings/call-transcripts/2025/10/23/valero-energy-vlo-q3-2025-earnings-call-transcript/?utm_source=openai)) - Kraft Heinz (KHC) — restructuring with announced split into two companies; 2025 outlook trimmed as demand softens; potential sum‑of‑parts unlocking later. ([apnews.com](https://apnews.com/article/79a6fe0491da98bcda8c77a8227994c3?utm_source=openai)) - Molson Coors (TAP) — Q3 goodwill/intangibles impairments mask underlying profitability; still targeting ~$1.3B 2025 FCF and active buybacks/dividends. ([ir.molsoncoors.com](https://ir.molsoncoors.com/news/news-details/2025/Molson-Coors-Beverage-Company-Reports-2025-Third-Quarter-Results/default.aspx?utm_source=openai)) - Zimmer Biomet (ZBH) — device cycle tailwind but execution choppiness; lifted 2025 EPS guide mid‑year then cut organic growth later; robotics M&A optionality. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/zimmer-biomet-raises-annual-profit-forecast-strong-demand-medical-devices-2025-08-07/?utm_source=openai)) - eBay (EBAY) — high FCF conversion, material buybacks (+$625M in Q3), ad take‑rate rising. ([investors.ebayinc.com](https://investors.ebayinc.com/investor-news/press-release-details/2025/eBay-Inc--Reports-Third-Quarter-2025-Results/default.aspx?utm_source=openai)) - Elevance (ELV) and peers for a basket idea — solid cost control, reaffirmed 2025 EPS guide in April; managed‑care multiples still below long‑term averages after 2024–25 volatility. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/elevance-confirms-quarterly-profit-beat-reaffirms-2025-forecast-2025-04-22/?utm_source=openai)) Pick for this edition: CVS Health (new deep‑dive) --- # CVS Health (CVS): full valuation deep‑dive ## What’s new and why now - Operations are stabilizing in 2025 after a tough 2024. Q3‑25 revenue hit a record $102.9B; YTD operating cash flow reached $7.2B. Management raised 2025 Adjusted EPS to $6.55–$6.65 and nudged CFFO guidance up to $7.5–$8.0B. A $5.7B non‑cash goodwill impairment (Health Care Delivery) drove GAAP loss but doesn’t affect cash. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) - Dividend held at $0.665 per share; Board reconfirmed quarterly payouts in January, March, July, and September 2025. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-Health-announces-quarterly-dividend/default.aspx?utm_source=openai)) - Portfolio clean‑up: Omnicare long‑term‑care pharmacy deconsolidated and filed Chapter 11, with CVS recognizing a gain on deconsolidation alongside the separate goodwill write‑down. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) Bottom line: The market still discounts CVS for retail/PBM/Medicare uncertainty. Our work tests whether 2025’s cash flow reset supports value for a multi‑year hold. --- ## Business in one page - What they do: An integrated health platform across insurance (Aetna), pharmacy benefit management (Caremark), and retail pharmacy/clinics. Cash comes from premiums, PBM spread/fees, and retail scripts/services. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) - 2025 run‑rate snapshot: FY25 guidance now calls for Adjusted EPS $6.55–$6.65; CFFO $7.5–$8.0B; Q3 highlighted strong Medicare Advantage Stars and solid PBM wins (≈$6B). ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) - Balance sheet and shares: YE‑24 cash $8.6B; 2024 CFFO $9.1B; basic shares ≈1.26–1.27B; Q3‑25 outstanding ≈1.269B. ([sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000007/cvs-20241231.htm?utm_source=openai)) --- ## Cross‑checking the current landscape - Managed‑care sentiment improving but still fragile after sector shocks; Elevance reaffirmed 2025 and beat Q1, while UnitedHealth volatility kept peer multiples subdued. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/elevance-confirms-quarterly-profit-beat-reaffirms-2025-forecast-2025-04-22/?utm_source=openai)) - Retail pharmacy peers are under pressure (Walgreens suspended its dividend in January), underscoring the benefit of CVS’s diversified model and scale. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/walgreens-suspends-quarterly-dividend-amid-turnaround-efforts-2025-01-30/?utm_source=openai)) --- ## Valuation: ground‑up DCF to equity (FCFE) + comparables We use a free‑cash‑flow‑to‑equity DCF anchored on 2025 cash‑flow guidance and a “normalized” mid‑cycle scenario. All figures are in USD billions unless noted. Key audited anchors - 2025 CFFO guidance: $7.5–$8.0B; YTD CFFO $7.2B through Q3. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) - 2024 capex: ~$2.8B (proxy for maintenance); 2024 CFFO: $9.1B. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2024-RESULTS/default.aspx?utm_source=openai)) - Shares outstanding: ~1.269B (Q3‑25). ([macrotrends.net](https://www.macrotrends.net/stocks/charts/CVS/cvs-health/shares-outstanding?utm_source=openai)) Practical modeling choices - FCFE ≈ CFFO – capex (CFFO already accounts for interest; we assume neutral net borrowing over the cycle). We test two Year‑1 bases: (A) current‑year “Reset” and (B) “Normalized.” - Capex: $2.8–$3.0B baseline, consistent with 2024. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2024-RESULTS/default.aspx?utm_source=openai)) - Discount rate (cost of equity): 9.0% base (range 8.5–10.0%), consistent with today’s rate backdrop and large‑cap health‑care risk. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/elevance-confirms-quarterly-profit-beat-reaffirms-2025-forecast-2025-04-22/?utm_source=openai)) - Growth: modest, reflecting PBM repricing and Medicare normalization. We vary short‑term growth 3–4% fading to 2.0–2.5% terminal. ### Scenario A — “Reset 2025” (as‑guided) - Year‑1 FCFE base: midpoint CFFO $7.75 – capex $2.85 ≈ $4.90. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) - Growth: +4% for Years 1–3, +3% for Years 4–5; terminal g = 2.0%; r = 9.0%. - PV(Years 1–5) ≈ $21.2; PV(Terminal) ≈ $55.4; Equity value ≈ $76.6. - Per share intrinsic ≈ $60 (using 1.269B shares). Interpretation: On “reset” cash flow only, CVS screens roughly fairly valued to slightly rich if the stock trades materially above $60. ### Scenario B — “Normalized mid‑cycle” - Year‑1 FCFE base: assume CFFO returns toward $9.0–$9.5B (between 2024 actual $9.1B and 2023 $13.4B); use $9.0B – capex $3.0B = $6.0 FCFE. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2024-RESULTS/default.aspx?utm_source=openai)) - Growth: +3% for Years 1–5; terminal g = 2.5%; r = 9.0%. - PV(Years 1–5) ≈ $25.4; PV(Terminal) ≈ $71.4; Equity value ≈ $96.8. - Per share intrinsic ≈ $76. Sensitivity inside Scenario B - If mid‑cycle FCFE is $6.5 (still conservative vs. 2021–22), per share ≈ $82–$83 at the same r and g. - If r = 9.5% (higher equity risk), base per share falls ≈ $5–$7. - If g = 2.0% (more PBM pressure), base per share falls ≈ $4–$5. DCF conclusion: A disciplined DCF brackets intrinsic value ~ $60 (reset) to ~$83 (normalized). Where you land depends on confidence that 2025’s cash flow is a trough and that mix/pricing resets hold. ### Comparable‑multiples checks (sanity) - CVS forward P/E ≈ stock price / FY25 Adjusted EPS guide ($6.55–$6.65). Versus managed‑care comps, UNH ~14.7x (TTM), ELV ~13.4x (TTM), CI ~13.3x (TTM). CVS typically trades below these due to retail/PBM exposure; a 10–12x range on $6.60 implies ~$66–$79. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) - EV/EBITDA cross‑check: third‑party trackers show CVS ~15x TTM; not cheap vs. pure payors but skewed by consolidation and impairment noise. Use with caution; our DCF is primary. ([valueinvesting.io](https://valueinvesting.io/CVS/valuation/ev_ebitda-multiples?utm_source=openai)) --- ## What could drive upside or downside to our range? Upside levers (evidence) - Stars rebound: Management highlighted industry‑leading Medicare Advantage Stars improving 2025 revenue quality. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) - PBM retention/wins: Caremark cited nearly $6B in contract wins with retention in the “high 90s,” supporting volume and fee stability. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) - Cash discipline: 2025 CFFO raised to $7.5–$8.0B despite litigation noise; room to normalize back toward ~$9B as headwinds abate. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) Downside risks (evidence) - Retail and LTC exposure: Sector stress is real (Walgreens suspended its dividend in January 2025). CVS is diversified, but retail drag could persist. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/walgreens-suspends-quarterly-dividend-amid-turnaround-efforts-2025-01-30/?utm_source=openai)) - Litigation/legacy assets: Omnicare Chapter 11 removes some noise but legal overhangs can flare and impair cash. ([reuters.com](https://www.reuters.com/legal/litigation/cvs-unit-omnicare-files-bankruptcy-resolve-litigation-2025-09-22/?utm_source=openai)) - Policy risk for PBMs/MA: Regulatory changes to spread pricing/rebates and MA rate setting could trim margins (we embed lower terminal growth for this). --- ## Roadmap to value creation (12–24 months) 1) Protect cash engine and prove trough is past - Deliver FY25 CFFO ≥ $7.5–$8.0B and exit 2026 ≥ $8.5–$9.0B with capex discipline ≈ $3B. This underwrites FCFE ≥ $6B in our normalized case. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) 2) Sustain Stars and MA profitability - Keep Stars at or above 4‑star weighted averages to support 2026–27 rates and membership. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) 3) Lock in PBM renewals and transparency positioning - Convert the 2025 selling season momentum into multi‑year retention while adapting to any transparency mandates. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) 4) Continue portfolio clean‑up/capital allocation - Finish Omnicare process; maintain dividend while weighing buybacks against leverage and execution priorities. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) --- ## Step‑by‑step audit of the DCF 1) Starting cash‑flow base: Used FY25 CFFO guide $7.5–$8.0B and YE‑24 actual $9.1B to set Scenario A ($7.75B) and Scenario B ($9.0B) starting points. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) 2) Capex: Anchored to 2024 ~$2.8–$3.0B. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2024-RESULTS/default.aspx?utm_source=openai)) 3) FCFE = CFFO − capex, assuming neutral net borrowing over a cycle. 4) Growth/terminal: 3–4% near‑term fading to 2.0–2.5% terminal, reflecting PBM repricing and MA normalization; we avoided aggressive growth. Evidence: guidance raises and Stars improvement. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) 5) Discount rate: 9.0% base (tested 8.5–10.0%) consistent with large‑cap health care and today’s macro. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/elevance-confirms-quarterly-profit-beat-reaffirms-2025-forecast-2025-04-22/?utm_source=openai)) 6) Share count: 1.269B (Q3‑25). Per‑share values computed as Equity Value ÷ shares. ([macrotrends.net](https://www.macrotrends.net/stocks/charts/CVS/cvs-health/shares-outstanding?utm_source=openai)) 7) Sanity checks: Compared to payor P/E bands (UNH, ELV, CI) and a high‑level EV/EBITDA snapshot. ([companiesmarketcap.com](https://companiesmarketcap.com/united-health/pe-ratio/?utm_source=openai)) --- ## Verdict and valuation range - One‑liner: CVS is a “prove‑it” value setup. If 2025 truly marks cash‑flow trough and execution sticks, intrinsic value clusters in the mid‑$70s to low‑$80s; if not, fair value is closer to ~$60. - Valuation: - DCF “Reset 2025” per share ≈ $60. - DCF “Normalized mid‑cycle” per share ≈ $76; upside case with sustained FCFE ~$6.5B ≈ $82–$83. - P/E cross‑check (10–12x on $6.60) ≈ $66–$79. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) - What to do: For strict value buyers, accumulate on pullbacks into the upper‑$60s (a discount to our normalized base and within our P/E band), and add as evidence mounts on: (i) FY25 CFFO ≥ $7.5–$8.0B, (ii) 2026 CFFO path ≥ $8.5–$9.0B, (iii) MA Stars durability and PBM retention. ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx?utm_source=openai)) If you want, I can share a compact spreadsheet so you can flex the FCFE, discount rate, and terminal growth assumptions and see how the per‑share value moves in your own scenarios.